To determine the frequency and prognostic significance of rearrangement, and p16 homozygous deletion because of the recently described genetic lesions in pediatric acute lymphobllimited data on these abnormalities. were randomized at the end of induction to receive either rearrangement, suggesting that these factors be added to ALL risk classification schemes.
therapy. 28 Treatment of subclinical central nervous system leukemia included intrathecal methotrexate/hydrocortisone/cytarabine given during the first year of therapy, Introduction with added cranial irradiation at 1 year for those with highrisk leukemia.
Genetic abnormalities of leukemic cells have important prog-
Immunophenotyping and cytogenetic analysis was perfornostic and therapeutic implications in childhood acute lymmed as previously described. 29, 30 In this analysis, B-precursor phoblastic leukemia (ALL). 1, 2 For example, hyperdiploidy ALL is defined as B lineage ALL lacking surface immunoglobconfers a favorable prognosis even in patients treated with ulin and represented 146 of the 188 patients treated on the conventional antimetabolite-based therapy. 3 Recently, we protocol. The immunophenotypic breakdown of patients anafound that ETV6 (TEL) gene rearrangements were also associalyzed molecularly was: 138 B precursor, 26 T cell, and six ted with an excellent outcome in two study populations, unclassifiable or without data. Written informed consent was although neither represented consecutive cases treated with obtained from patients or their legal guardians, and all studies uniform therapy. 4, 5 By contrast, the t(9;22), t(4;11), and other (therapeutic and diagnostic) were approved by our MLL gene rearrangements are associated with a poor progInstitutional Review Board. nosis in patients treated with a variety of regimens. [6] [7] [8] [9] [10] [11] [12] The prognostic significance of the t(1;19) appears to depend on treatment intensity: contemporary intensive chemotherapy Molecular analyses regimens have abolished the poor prognosis once ascribed to this translocation. [13] [14] [15] Whereas the clinical relevance of the Ficoll-Hypaque-enriched leukemic blasts were obtained from common fusion genes in ALL is well-recognized, the progdiagnostic bone marrow aspirates from 170 of the 188 patients nostic impact of homozygous deletions of the p16 tumor enrolled on this study. A subset of these patients were presuppressor gene is still uncertain. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] viously analyzed for ETV6 gene rearrangements. 4 Genomic In this study, we sought to determine the prevalence and DNA was analyzed for ETV6 gene rearrangements as preclinical impact of the most common genetic abnormalities in viously described. 31 Briefly, 10 g of high-molecular weight a series of consecutive cases of childhood ALL enrolled on a DNA was digested with BamHI, separated electrophoretically single institutional protocol. Emphasis was placed on cases in 0.8% agarose gels and transferred to nylon membranes. with ETV6-AML1 (ETV6-CBFA2) expression, MLL gene Membranes were then hybridized with an ␣-32 P dCTP-labeled 466-basepair SacI/BamHI ETV6 cDNA fragment (probe pSB). 31 After high stringency washes, membranes were analyzed by autoradiography. Samples that demonstrated ETV6 rearrangement by Southern blot were analyzed by reverse of cases had greater than 90% leukemic blasts, five samples had less than 70% blasts and thus could not be quantified by this method. An additional 10 cases had no material on which to perform p16 analysis after other molecular studies were done.
Deletions of p16
Quantitative Southern blot analysis was performed as described above to determine if deletion of the p16 tumor Statistical methods suppressor gene is prognostically important in childhood ALL. Because this analysis was limited to Southern blotting, only Event-free survival (EFS) is measured from the date of comcases with greater than 70% leukemic blasts could be evaluplete response (CR) to the date of first failure (death, relapse ated. In addition, quantitative blotting alone cannot accurately or second malignancy) or the date of last contact. Patients identify hemizygously deleted cases; therefore, we compared who did not achieve a CR were assigned an EFS value of zero.
cases with homozygous p16 deletion to cases with at least The methods of Kaplan and Meier were used to estimate the one copy of p16. Overall, homozygous p16 deletions were distributions of EFS, with standard errors (SE) calculated as seen in 36 of 155 cases (23%), including 21 of 128 B lineage suggested by Peto. Patients who achieved a CR were stratified (16%) and 14 of 23 T cell (61%) cases (Table 2) . Although as follows: by race (non-white vs white); within white patients associated with T lineage (P Ͻ 0.001) and higher leukocyte by DNA index (р1.15 vs Ͼ1.15); and within white patients counts (P = 0.003), homozygous p16 deletion was not correwith DNA index р1.15 by age and leukocyte count (2-10 lated with treatment outcome. Five-year EFS estimates for years vs Ͻ2 or у10 years and leukocyte count Ͻ25 000/mm 3 patients with and without p16 deletions were 64 ± 10% and vs у25 000/mm 3 ). Patients were then randomized to conven-70 ± 5%, respectively (P Ͼ 0.8, Figure 1 ). In addition, p16 tional treatment dosing or targeted systemic exposure dosing status was not prognostically important within B lineage or T within each stratum. The term 'stratified' is used in the text to lineage cases. indicate adjustment for these strata. For the purposes of this analysis, central nervous system status was defined as blasts vs no blasts in the cerebrospinal fluid at diagnosis.
All analyses which control for treatment assignment are MLL gene status conditionable upon patients having achieved a complete remission and evaluate prognosis measured by duration of Cytogenetic analysis demonstrated the presence of translocontinuous complete remission (CCR). Fisher's exact test was cations involving chromosome band 11q23, the site of the used to evaluate correlations among the genetically defined MLL gene, in seven cases, including four cases with t(4;11), subgroups of patients and presenting clinical and genetic featwo with t(9;11), and one with t(11;19). Southern blot analysis tures. Distributions of EFS and duration of CCR were comof 170 cases confirmed the presence of MLL rearrangements pared by stratified Cox proportional hazards models using in these seven cases and also identified two additional cases Wald statistics. All statistical analyses were conducted using with rearrangements of the gene. One of these cases had a SAS 6.11. All survival results are presented in the form of '5-normal karyotype at diagnosis and the other demonstrated a year estimate ± 1 s.e.' Median follow-up times for each sub9p21 deletion. Rearrangements of MLL (Table 2) were seen group are as follows: p16 deleted, 5.89 years; p16 not deleted, only in B lineage cases and were associated with younger age 5.31 years; rearranged ETV6, 5 .65 years; germline ETV6, 5.30 (P = 0.001) and higher leukocyte counts (P = 0.029). Of the years; rearranged MLL, 5 .94 years; germline MLL, 5.34 years.
nine patients with MLL rearrangements, six were less than 1 year old (four with t(4;11) and two with t(9;11)), two were between 1 and 10 years of age (no 11q23 abnormalities), and Results one was older than 10 years (t (11;19) ). Because of the rarity of MLL rearrangements, we were unable to assess the prognostic importance of this genetic event after adjusting for known Of the 188 children enrolled on this study, 186 had successful cytogenetic or molecular genetic studies performed. Table 1 clinical risk features. However, among B lineage patients, MLL rearrangement was significantly correlated with EFS summarizes the frequency and outcome of the most common genetic subgroups. The 5-year EFS for all 188 patients regis-(P = 0.0001). Five-year EFS estimates are 11 ± 7% and 74 ± 5% for B lineage patients with and without MLL tered on Study XII was 67 ± 4%, and 182 (97%) achieved a complete remission. rearrangement (Figure 2 ). on the curves indicate EFS ± 1 standard error.
The distributions of age, DNA index, and T lineage differed significantly between patients with rearranged ETV6 and those with germline ETV6 (Table 2 ). Importantly, only two patients with rearranged ETV6 had DNA indices greater than 1.15. The prognostic impact of ETV6 rearrangement was evaluated within B lineage patients only. In a stratified Cox proportional hazards model, presence of a rearranged ETV6 gene was significantly correlated with a favorable prognosis (P = 0.004). Five-years EFS estimates are 87 ± 7% and 64 ± 6% for B lineage cases with rearranged and germline ETV6, respectively points not detected by the primers used for RT-PCR. By contrast, MLL gene rearrangements were seen in 5% of cases and conferred a dismal prognosis, with eight of nine with the t(9;22) have failed therapy (one induction death and two relapses) and three patients remain in CCR. Similarly, two patients failing therapy. Three of these nine patients were more than 1 year old; all three relapsed despite intensive patients with the t (1;19) have relapsed and the other three are in CCR.
chemotherapy. Although no firm conclusions can be drawn from only three patients, these data do support our previous Hyperdiploidy (greater than 50 chromosomes) was seen in 55 patients (29%) ( Table 1 ). As expected, hyperdiploidy was report (which did not include these three patients) that suggested a poor outcome for patients with MLL gene rearrangeassociated with a favorable outcome, with a 5-year EFS estimate of 81 ± 7%. ments regardless of age.
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Although many studies have demonstrated a high frequency of p16 gene inactivation in ALL, the majority of these studies were unable to address definitively the prognostic significance Discussion of p16 deletion. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] In our previous study, using both Southern blot and fluorescence in situ hybridization (FISH) techRisk-based treatment protocols for pediatric ALL rely on clinical and genetic features to predict a patient's risk of relapse.
niques, we showed an association between the presence of p16 deletion and T cell phenotype and a trend towards worse Genetic features used in current risk-classification schemes include the presence or absence of hyperdiploidy, 3 trisomies outcome in patients with p16 deletion. 17 Other studies, however, suggested that p16 deletion is not independently progof chromosomes 4 and 10, 32 rearrangements of the MLL gene, [8] [9] [10] [11] [12] and the 9;22 and 1;19 translocations. 6, 7, 13, 14 nostically important.
18,22 Recently, Heyman et al 27 suggested that homozygous p16 inactivation is, in fact, an independent Recently, we have suggested that rearrangements of the ETV6 gene, or expression of ETV6-AML1, should also be incorporprognostic factor in pediatric ALL. Because of these conflicting reports, we wished to determine the prognostic impact of ated into these schemes, as this molecular abnormality is independently predictive of a favorable outcome. 4, 5 Our first homozygous p16 deletions in a group of uniformly treated patients. Although we showed that p16 deletions were assostudy, however, included patients treated with a variety of regimens. 4 The second study was a case-control analysis of a ciated with T cell phenotype and higher leukocyte counts, p16 status was not an independent predictor of outcome (Tables 1  selected group of patients. 5 That study demonstrated that ETV6 gene rearrangement connoted a favorable prognosis and 2; Figure 1 ). Despite the association with higher leukocyte counts, it is not surprising that there is no prognostic signifieven among patients treated with antimetabolite-based therapy, but was unable to provide actuarial event-free survival cance of p16 deletion, as leukocyte counts appear to have no prognostic value in T cell ALL. 39 It should be noted, however, of unselected patients with this genetic abnormality. Recently, McLean et al 33 have shown that ETV6-AML1 expression is that the p16 examination was limited to Southern blot analysis only, and thus did not include cases with hemizygous associated with a favorable outcome in a study of patients treated on one of four different protocols at the Dana-Farber deletions.
We have demonstrated that ETV6 rearrangements are assoCancer Institute.
In the present study, we have analyzed 99% of patients ciated with a favorable outcome in combined studies of patients treated across several different St Jude protocols, 4, 31 treated on a single institutional protocol that consisted of antimetabolite-based therapy reinforced with only five pulses of in an analysis of patients treated with conventional antimetabolite-based therapy (Pediatric Oncology Group protocol teniposide-cytarabine. Our results demonstrate that both ETV6 and MLL gene status contribute significant prognostic infor-8602), 5 and presently among patients treated on St Jude Total Therapy XII. However, the basis for the outstanding prognosis mation with regard to disease-free survival in an analysis stratified for other prognostic factors. Rearrangement of the of this group of patients remains to be elucidated. We are currently analyzing leukemic blasts containing rearranged or ETV6 gene, representing ETV6-AML1 fusion in most cases, was not detected by conventional cytogenetics, but was the germline ETV6 for in vitro chemoresponsiveness, methotrexate polyglutamate accumulation, 40 and growth potential of most common genetic lesion, occurring in 21% of patients. In addition, ETV6 rearrangement identified a subgroup of leukemic blasts in stromal cell culture systems. 41 These studies may provide clues to the mechanism by which ETV6-AML1 patients, the majority of whom did not have hyperdiploidy, with an excellent outcome that was comparable to patients expression leads to improvements in patient outcome. Studies are also needed to identify factors that are predictive of the with hyperdiploidy Ͼ50 (Table 1 ). In fact, among the 34 B lineage cases with rearranged ETV6, only two patients occasional relapse in this group of patients. The role of ETV6-AML1 in leukemic transformation is also relapsed. It is well-recognized, however, that the most important prognostic factor is treatment efficacy. Thus, it will the subject of intense investigation. This fusion gene encodes a chimeric protein that contains the helix-loop-helix domain be important to confirm these results in the context of other treatment protocols.
of ETV6 fused to nearly all of AML1. Although the normal function of ETV6 is unknown, it shares homology with the ETS Expression of ETV6-AML1 appears to be restricted to B lineage ALL cases and occurs primarily in pediatric patients. 31,34- family of transcription factors and is involved in several other translocations, including the t(5;12), 42 t(9;12), 43 t(10;12), 44 38 In addition, nearly all B lineage cases with rearrangements of ETV6 detected by Southern blot analysis express the ETV6-and t(12;22). 45 AML1 contains two important domains, an amino-terminal DNA-binding domain and a carboxy-terminal AML1 fusion transcript. 31 In the present study, we observed
